Delving into the Latest Updates on Mirdametinib with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Mirdametinib (USAN), PD 901, PD-0325901

+ [3]

Target

MEK1 x MEK2

Action

inhibitors

Mechanism

MEK1 inhibitors(Dual specificity mitogen-activated protein kinase kinase 1 inhibitors), MEK2 inhibitors(Dual specificity mitogen-activated protein kinase kinase 2 inhibitors)

Therapeutic Areas

NeoplasmsNervous System DiseasesCongenital Disorders+ [6]

Active Indication

Neurofibromatosis 1NF1 mutant Plexiform NeurofibromaDedifferentiated Liposarcoma+ [11]

Inactive Indication

Advanced breast cancerAdvanced cancerAdvanced Lung Non-Small Cell Carcinoma+ [4]

Originator Organization

Springworks Therapeutics, Inc.

Active Organization

BeOne Medicines Ltd.

Springworks Therapeutics, Inc.SPRINGWORKS THERAPEUTICS IRELAND LTD

Inactive Organization

Pfizer Inc.

License Organization

SpringWorks Therapeutics LLCMerck KGaA

Springworks Therapeutics, Inc.

+ [2]

Drug Highest PhaseApproved

First Approval Date

United States (11 Feb 2025),

Neurofibromatosis 1

RegulationPriority Review (United States), Fast Track (United States), Orphan Drug (United States), Orphan Drug (European Union), Rare Pediatric Disease (United States)

Login to view timeline

Structure/Sequence

Molecular FormulaC16H14F3IN2O4

InChIKeySUDAHWBOROXANE-SECBINFHSA-N

CAS Registry391210-10-9

Background:
Multiple myeloma (MM) is a type of blood cancer that affects a person s immunity. MM returns after treatment (relapse) in almost all people; MM may also not respond to initial treatment (refractory). Many people with relapsed refractory MM (RRMM) also have changes in their KRAS and NRAS genes. Researchers want to try a new drug treatment that targets cancer with these changed genes.
Objective:
To test 2 drugs (mirdametinib and sirolimus) in people with RRMM.
Eligibility:
People aged 18 and older with RRMM who have changes in their KRAS or NRAS genes.
Design:
Participants will be screened. They will have blood tests and imaging scans. They will have an eye exam and a test of their heart function. They will need to provide proof of their disease status and of their KRAS or NRAS status. If neither is available, the tests will be repeated.
Participants will have a bone marrow biopsy: A needle will be inserted into a hipbone to draw out some soft tissue.
This study will be done in two parts. In the first part of this study, we will find a safe dose of mirdametinib combined with sirolimus. In the second part, we will learn more about how mirdametinib combined with sirolimus may work against RRMM.
Mirdametinib (capsules) and sirolimus (tablets) are taken by mouth. Participants will take both drugs at home on a 4-week cycle. They will take mirdametinib twice a day for the first 3 weeks of each cycle. They will take sirolimus once a day, every day, during each cycle.
Participants will have study visits once a week during the first cycle, and then on the first day of subsequent cycles. Blood, heart, imaging scans, and other tests will be repeated.
Treatment with the study drugs will go on for 1 year. Then participants will have follow-up visits every 3 months for 4 more years.

Start Date09 Jul 2025

Sponsor / Collaborator

National Cancer Institute

NCT06997276

/ RecruitingPhase 1

A Phase 1 Open-Label Study to Assess the Pharmacokinetics of Mirdametinib and Its Metabolite PD-0315209 in Participants With Impaired Hepatic Function and Participants With Normal Hepatic Function

The purposes of this study are to determine:
* The pharmacokinetics (the amount of study drug in your blood and how long it takes the body to get rid of it) of the study drug and its metabolites (substances produced as the body breaks down the study drug) in participants with moderate or severe liver function impairment compared to participants with normal liver function (also known as a healthy volunteer). Pharmacokinetics (or PK) is the study of how your body absorbs, breaks down, and removes a study drug.
* How well the study drug is tolerated and any side effects that may occur in participants with moderate or severe liver function impairment compared to participants with normal liver function.
This study is for research purposes only and is not intended to treat any medical condition.

Start Date07 May 2025

Sponsor / Collaborator

Springworks Therapeutics, Inc.

NCT06666348

/ Not yet recruitingPhase 1/2

A Phase 1/2 Study of Mirdametinib and Vinblastine for Newly Diagnosed or Previously Untreated Patients With Pediatric Low-grade Glioma and Activation of the MAPK Pathway

This is a 3-part open-label study (feasibility phase, treatment phase and follow-up phase) of orally administered mirdametinib in combination with intravenous vinblastine chemotherapy in patients with PLGG with activation of MAPK pathway.
Feasibility Phase:
The maximum tolerated/recommended phase 2 dose (MTD/RP2D) of the mirdametinib plus vinblastine combination will be assessed using a modified Rolling-6 design.
Treatment Phase:
Patients will receive mirdametinib twice daily (continuously) at a fixed dose (2mg/m2 po BID up to 4 mg BID) for a total of 13 cycles (28 days cycle). Weekly intravenous vinblastine at MTD will be given for a total of 17 cycles. If adverse events occur, two dose reductions are allowed.
Follow-up Phase:
Following the end of treatment, patients will be scheduled for a follow-up visit every 6 months for 36 months to evaluate PFS, TTP and OS.

Start Date01 Apr 2025

Sponsor / Collaborator

C17 Council

100 Clinical Results associated with Mirdametinib

Login to view more data

100 Translational Medicine associated with Mirdametinib

Login to view more data

100 Patents (Medical) associated with Mirdametinib

Login to view more data

987

Literatures (Medical) associated with Mirdametinib

01 Aug 2025·GENE

Exploring the functional and prognostic roles of EPHX4 in pancreatic cancer: Insights from bioinformatics and experimental validation

Article

Author: Gu, Dandan ; Huang, Shaoyang ; Xiong, Wei

BACKGROUND:

Epoxide hydrolase-4 (EPHX4) belongs to the epoxide hydrolase enzyme family, but its biological function remains unclear, especially its potential involvement in the development of pancreatic tumours. This research sought to examine the function of EPHX4 in pancreatic adenocarcinoma (PAAD).

METHODS:

The expression of EPHX4 across cancers was examined through The Cancer Genome Atlas (TCGA). Bioinformatics was employed, leveraging multiple databases to investigate EPHX4 gene expression in pancreatic cancer and its association with survival prognosis, functional enrichment, immune infiltration, tumour mutation load, and drug sensitivity, among other variables. To evaluate EPHX4 expression in PAAD cells, Western blotting and reverse transcription quantitative PCR were used. A series of in vitro functional experiments was performed to assess the proliferation, migration, and invasion of PAAD cells.

RESULTS:

EPHX4 expression was markedly elevated in a number of malignancies, including PAAD, and was associated with patient sex, clinical stage, and metastasis to the lymph nodes. High EPHX4 expression was significantly associated with a worse outcome in PAAD patients. According to functional and enrichment studies, EPHX4 is involved in many signalling pathways linked to cancer. The study of immune infiltration revealed that EPHX4 was connected to the existence of a variety of immune cells inside the tumour. Our study revealed that EPHX4 knockdown significantly decreased PAAD cell migration, proliferation, and invasion.

CONCLUSION:

EPHX4 is highly expressed in PAAD and independently predicts poor survival. Functional experiments demonstrate its tumor-promoting effects. Its involvement in multiple cancer-related signaling pathways and immune regulation mechanisms highlights the dual prognostic and therapeutic potential of EPHX4 in PAAD.

01 Jul 2025·DEVELOPMENTAL BIOLOGY

Characterisation of the avascular mesenchyme during digit outgrowth

Article

Author: Batho-Samblas, Cameron ; Smith, Jonathan ; Keavey, Lois ; Clancy, Noah ; McTeir, Lynn ; Davey, Megan G

The avascular mesenchyme at the tip of the developing digit contributes to digit outgrowth and patterning, however, it has been poorly characterised. Using newly developed fate mapping approaches, tissue manipulation and single-cell mRNA sequencing data, we explore the transcriptional nature and developmental potential of this tissue. We find that the avascular mesenchyme is essential to normal segmental patterning of the digit and has a distinct transcriptional identity. In addition, we uncover an unexpected relationship between the unspecified tissue of the avascular mesenchyme and the committed phalanx forming region, which controls patterning, but not outgrowth of the digit. This multifaceted approach provides insights into the mechanics and genetic pathways that regulate digit outgrowth and patterning.

01 Jun 2025·Animal Bioscience

Key events in the process of sex determination and differentiation in early chicken embryos

Article

Author: Gong, Wei ; Sun, Hongyan ; Li, Zeyu ; Qian, Hongwu ; Liu, Xin ; Zuo, Qisheng ; Li, Bichun ; Han, Wei ; Song, Jiuzhou ; Liu, Guanzheng ; Niu, Yingjie ; Chen, Guo Hong ; Zhu, Xilin ; Lv, Xiaoqian ; Jin, Kai ; Wu, Jun ; Sun, Changhua

Objective: Current understanding of sex determination and differentiation mechanisms during early chicken embryonic development remains incomplete. To address this, we applied RNA sequencing to identify male-female expression differences at critical developmental stages (E0 blastocysts, E3.5-E6.5 genital ridges, E18.5 gonads), focusing on glycolysis, histone acetylation, and DNA methylation. This approach aims to unravel key regulatory mechanisms and advance developmental biology insights.Methods: We analyzed molecular mechanisms of chicken sex determination at key stages (E0 blastocysts, E3.5-E6.5 genital ridges, E18.5 gonads) using RNA sequencing. Glycolysis, histone acetylation, and DNA methylation levels were assessed in embryonic stem cells and chicken embryonic fibroblasts. E18.5 gonads were treated with glycolytic activators (SB431542 and PD0325901 [2i]), a DNA demethylation activator (Vitamin C [Vc]), or an inhibitors of histone acetylation modification (valproic acid [VPA]). Sex-related gene expression, hormone levels, and gonad morphology were evaluated to determine treatment effects.Results: Key findings revealed that sex differences emerged as early as the blastocyst stage, intensified with embryonic development and were marked by a surge in sexually dimorphic gene expression. Gene Ontology and Kyoto encyclopedia of genes and genomes analyses highlighted the pivotal roles of energy metabolism and epigenetic modification process during this critical period. 2i, VC, or VPA interventions targeting E18.5 embryo gonads, induced a remarkable transformation of ovarian tissue into a testis-like structure, characterized by cortical thinning, medulla densification, downregulation of female-specific genes (FOXL2, WNT4), upregulation of male-specific genes (SOX9, AMH), and increased testosterone secretion. This phenotypic and molecular shift underscores the ability of metabolic and epigenetic modulators to reprogram ovarian development towards a male-like pattern, preserving male sexual characteristics.Conclusion: Our study establishes energy metabolism and epigenetic regulation as central drivers of avian sex determination. These findings advance understanding of vertebrate developmental biology and provide a framework for dissecting regulatory networks in avian sexual development.

86

News (Medical) associated with Mirdametinib

02 Jul 2025

·www.pharmaceutical-technology.com

Merck concludes SpringWorks acquisition for $3.4bn

Merck executive board chair and CEO Belén Garijo. Credit: Merck KGaA. Merck KGaA has concluded the previously announced acquisition of SpringWorks Therapeutics for an enterprise value of €3bn ($3.4bn), after receiving regulatory approvals and fulfilling customary closing conditions. The merger, announced in April 2025 , will positively impact Merck’s financial position by contributing to revenues immediately, and is anticipated to be accretive to its earnings per share by 2027. Merck will add two SpringWorks’ products targeting rare tumours with limited treatment options. Ogsiveo (nirogacestat) is approved by the Food and Drug Administration (FDA) for adults with progressing desmoid tumours requiring systemic treatment. The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) also recommended its approval in June 2025. Gomekli (mirdametinib) is approved by the FDA for neurofibromatosis type 1 (NF1)-related symptomatic plexiform neurofibromas (PN) in adults and children aged two years and above deemed unsuitable for complete resection. Mirdametinib also received a positive opinion from CHMP in May 2025. Merck executive board chair and CEO Belén Garijo stated: “The acquisition of SpringWorks illustrates our decisive portfolio approach to further position Merck as a globally diversified science and technology powerhouse. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strategic Intelligence “This is the largest acquisition we have made for our healthcare business sector in nearly 20 years, marking an exciting new chapter. Furthermore, we remain committed to identifying mergers and acquisitions opportunities across our three business sectors, with a focus on life science, prioritising strategic fit, financial robustness and long-term value creation.” The integration of SpringWorks’ portfolio enhances Merck’s strategic focus on developing treatments for rare tumours, including commercialisation rights for pimicotinib developed by Abbisko Therapeutics aimed at tenosynovial giant cell tumour patients. As a result of this transaction, trading of SpringWorks shares on Nasdaq has ceased, with shareholders receiving $47 per share in cash from Merck. Pharmaceutical Technology Excellence Awards - Have you nominated? Nominations are now open for the prestigious Pharmaceutical Technology Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact . This is your chance to showcase your achievements, highlight industry advancements , and gain global recognition . Don't miss the opportunity to be honoured among the best - submit your nomination today! Nominate Now

Drug ApprovalAcquisition

30 Jun 2025

·www.merckgroup.com

Merck Completes Acquisition of SpringWorks Therapeutics to Accelerate Sustainable Growth of its Healthcare Business

Merck, has closed the acquisition of SpringWorks Therapeutics, Inc., for an enterprise value of $3.4 billion (approximately €3 billion). Merck, a leading science and technology company, today announced that it has closed the acquisition of SpringWorks Therapeutics, Inc., for an enterprise value of $3.4 billion (approximately €3 billion)*, following regulatory clearances and the fulfillment of other customary closing conditions. The definitive agreement between Merck and SpringWorks, based in Stamford, Connecticut, was announced on 28 April, 2025. It represents one of the biggest M&A deals in the global biopharma sector so far in 2025. The business combination will immediately contribute to Merck’s revenues and is expected to be accretive to the company’s earnings per share pre (EPS pre) by 2027. “Today, we officially welcome SpringWorks to Merck. The acquisition of SpringWorks illustrates our decisive portfolio approach to further position Merck as a globally diversified science and technology powerhouse,” said Belén Garijo, Chair of the Executive Board and CEO of Merck. “This is the largest acquisition we have made for our Healthcare business sector in nearly 20 years, marking an exciting new chapter for Healthcare. Furthermore, we remain committed to identifying M&A opportunities across our three business sectors, with a focus on Life Science, prioritizing strategic fit, financial robustness, and long-term value creation.” “This acquisition is a significant step forward in bringing innovation to patients living with rare and often debilitating tumors—many of whom are young and facing a long, uncertain journey with limited treatment options,” said Danny Bar-Zohar, CEO of Healthcare and member of the Executive Board at Merck. “By combining our global reach with SpringWorks’ expertise, we are expanding access to life-changing therapies for patients around the world. At the same time, this move strengthens our foundation for further expansion in rare tumors and adjacent disease areas. I’d like to warmly welcome the SpringWorks team to Merck.” SpringWorks’ portfolio features two highly innovative products for the treatment of rare tumors in areas of high unmet need where limited treatment options exist. U.S. Food and Drug Administration (FDA)-approved, OGSIVEO® (nirogacestat) is a first-in-class therapy for the treatment of adult patients with progressing desmoid tumors who require systemic treatment. In June 2025, the European Medicine Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of nirogacestat. GOMEKLI™ (mirdametinib) is the first and only FDA-approved therapy for the treatment of adult and pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) not amenable to complete resection. In May 2025, the CHMP adopted a positive opinion recommending the approval of mirdametinib. SpringWorks’ portfolio complements Merck’s progress in building a rare tumor business with Merck having worldwide commercialization rights for pimicotinib, an investigational therapy developed by Abbisko Therapeutics Co., Ltd. for patients with tenosynovial giant cell tumor (TGCT). Global regulatory filings for pimicotinib are underway. The joint portfolio will serve a broad range of patients with rare tumors who have high unmet medical needs. Shares in SpringWorks will no longer be traded on the Nasdaq, with Merck now being the sole owner of SpringWorks. SpringWorks shareholders are being paid US$ 47 per share in cash.

Drug ApprovalAcquisition

18 Jun 2025

·www.einpresswire.com

BrightSpring Health Services Announces Onco360® Selected as National Pharmacy Partner for Multiple New Cancer and Rare Disease Drugs

LOUISVILLE, Ky., June 18, 2025 (GLOBE NEWSWIRE) -- BrightSpring Health Services (“BrightSpring” or “BrightSpring Health Services”) (NASDAQ: BTSG) is proud to announce that its specialty pharmacy, Onco360® , has been selected as the national pharmacy partner for several newly approved therapies in the treatment of advanced cancers and rare genetic disorders. Onco360® will help provide access, education, data, and expert support for innovative treatments for patients diagnosed with advanced ovarian and lung cancers, as well as neurofibromatosis type 1. “At Onco360®, we continue to partner with innovators and manufacturers to deliver groundbreaking medicines and therapies to patients facing serious, life-threatening conditions, giving them additional hope,” said BrightSpring President and CEO Jon Rousseau. “We’re proud of the rapid and pioneering work done every day by our specialty teams at Onco360® and CareMed pharmacies to expand care options and treatment alternatives for patients with cancer, rare, and complex disease.” Onco360®, a leading independent specialty pharmacy, has been selected as a pharmacy partner for the following medication therapies: GOMEKLI™ is approved for the treatment of adult and pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) not amenable to complete resection. AVMAPKI™ FAKZYNJA™ CO-PACK is approved for the treatment of adult patients with KRAS -mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior systemic therapy. IBTROZI™ is approved for the treatment of adult patients with locally advanced or metastatic ROS1 -positive non-small cell lung cancer (NSCLC). About BrightSpring Health Services: BrightSpring Health Services provides complementary and integrated home- and community-based pharmacy and health solutions for complex populations in need of specialized and/or chronic care. Through the Company’s service lines, including pharmacy, home health care and primary care, and rehabilitation and behavioral health, we provide comprehensive care and clinical solutions in all 50 states to over 400,000 customers, clients, and patients daily. About Onco360® Oncology Pharmacy: Onco360® is a national and leading independent Oncology Pharmacy and clinical support services company. Onco360® was founded in 2003 to bring together stakeholders involved in the cancer treatment process and serve the specialized needs of oncologists, patients, hospitals, cancer centers of excellence, manufacturers, health plans, and payers. It dispenses nationally through its network of URAC-, and ACHC-accredited Specialty Pharmacies. Onco360® is headquartered in Louisville, Kentucky and is a flagship specialty pharmacy brand of PharMerica Corporation, a leading home and community pharmacy, specialty infusion, and hospital services company servicing customers and patients across the United States. For more information about Onco360®, please visit Onco360.com. Media Contact Leigh White Leigh.white@brightspringhealth.com 502.630.7412 Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Drug Approval

100 Deals associated with Mirdametinib

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D11675	-	-	DB07101

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Neurofibromatosis 1	United States	Springworks Therapeutics, Inc.	11 Feb 2025

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
NF1 mutant Plexiform Neurofibroma	NDA/BLA	United States	Springworks Therapeutics, Inc.	04 Mar 2024
Dedifferentiated Liposarcoma	Phase 2	United States	Springworks Therapeutics, Inc.	19 Feb 2025
Myxoid Liposarcoma	Phase 2	United States	Springworks Therapeutics, Inc.	19 Feb 2025
Advanced Malignant Solid Neoplasm	Phase 2	United States	Springworks Therapeutics, Inc.	03 Feb 2023
Advanced Malignant Solid Neoplasm	Phase 2	Australia	Springworks Therapeutics, Inc.	03 Feb 2023
Melanoma, Cutaneous Malignant	Phase 2	United States	Springworks Therapeutics, Inc.	03 Feb 2023
Melanoma, Cutaneous Malignant	Phase 2	Australia	Springworks Therapeutics, Inc.	03 Feb 2023
Low grade glioma	Phase 2	United States	Springworks Therapeutics, Inc.	21 Jun 2021
Colorectal Cancer	Phase 2	Netherlands	Pfizer Inc.	02 Apr 2014
KRAS mutant Non-small Cell Lung Cancer	Phase 2	Netherlands	Pfizer Inc.	02 Apr 2014

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03962543 (ReNeu, AAN2025)	Phase 2	NF1 mutant Plexiform Neurofibroma	-	Mirdametinib capsule	sovobofqnm(xbjnxkqdqc) = mqtafhwbsh orqxxrupct (bjrwqkedyj, 29% - 55%) View more	Positive	07 Apr 2025
				Mirdametinib dispersible tablet	sovobofqnm(xbjnxkqdqc) = mzopcojkxw orqxxrupct (bjrwqkedyj, 38% - 65%) View more
NCT03962543 (ReNeu, Pubmed \| J Clin Oncol)	Phase 2	NF1 mutant Plexiform Neurofibroma	-	Mirdametinib capsules	kaigvddtxq(bomyfyphgi) = rmjubbcory xwcpunmxny (ihnophjozm )	Positive	20 Feb 2025
				Mirdametinib tablets for oral suspension	kaigvddtxq(bomyfyphgi) = zjhcwzuqzi xwcpunmxny (ihnophjozm )
NCT03962543 (ReNeu, SNO2024 \| FDA_CDER) Manual	Phase 2	Neurofibromatosis 1	114	mirdametinib (adults)	ywsgcvnfly(flpmgzhaao) = zcpcvxeywu pyonavntot (kchnwojywu, 29 - 55) View more	Positive	11 Nov 2024
				mirdametinib (children)	ywsgcvnfly(flpmgzhaao) = auvsxxcbpj pyonavntot (kchnwojywu, 38 - 65) View more
NCT03962543 (ReNeu, SNO2024) Manual	Phase 2	NF1 mutant Plexiform Neurofibroma	114	MIRDAMETINIB (adults)	sgxdaflrpu(qywktmbtfe) = Clinically meaningful improvement was defined as change from baseline >9.7 points for adults, >8.5 points for child self-report, and >9.0 points for parent proxy-report. PedsQL-TS improvement (least-squares mean, LSM [SE] change) from baseline at C13 was 3.9 (1.6; P=.018; n=34) for adults, 4.0 (2.4; P=.096; n=38) for children by self-report, and 5.6 (1.9; P=.005; n=43) by parent proxy-report. PedsQL-TS improvements for adults and children by parent proxy-report (not by children self-report) were observed early (at C5 and C3, respectively) and sustained through C24. Clinically meaningful improvement in PedsQL-TS from baseline at C13 was achieved by 37% (10/27) adults, 45% (13/29) children by self-report, and 47% (15/32) children by parent proxy-report (among patients who could have achieved a clinically meaningful change from baseline). Significant (P<.05) improvement from baseline to C13 was reported for physical (adults, children, and parent proxy-report), school/work (adults), and emotional and social (parent proxy-report) subscales. tuuvyfqbul (xghzckdomd )	Positive	11 Nov 2024
				MIRDAMETINIB (children)
NCT04923126 (SJ901, SNO2024) Manual	Phase 1	Low grade glioma BRAF alteration \| FGFR1 alteration \| NF1 alteration ... View more	23	MIRDAMETINIB	iesztmkvtd(crbkmowbim) = bhsqasjzya dyqabeyiqg (xcgjicxijm ) View more	Positive	11 Nov 2024
NCT03962543 (ReNeu, SNO2024)	Phase 2	Plexiform Neurofibroma	12	MIRDAMETINIB (Prepubescent patients)	nrivhkmhkl(wwzswfsace) = wfdhkwfkds bssssiuuhf (zajygglkny )	-	11 Nov 2024
NCT03962543 (RENEU, EANO2024)	Phase 2	NF1 mutant Plexiform Neurofibroma	114	Mirdametinib 2 mg/m^2 BID	xoqzehxayf(prcdhqqfjt) = ytcurdrphr pwdkbsefom (rvdfqgfwsi, 29 - 55) View more	Positive	17 Oct 2024
				Placebo	xoqzehxayf(prcdhqqfjt) = oqobtzhssy pwdkbsefom (rvdfqgfwsi, 38 - 65) View more
NCT05054374 (CTgov)	Phase 1/2	Advanced Malignant Solid Neoplasm \| Metastatic breast cancer \| HER2-negative breast cancer	6	Fulvestrant+Mirdametinib (Arm 1, Part 1 - Mirdametinib in Combination With Fulvestrant)	ttdopoeezm(ouefzxiusp) = cnqdtsfzmc isctaphhwo (miziyrplxk, whwrygpftg - lrxfehkdkq) View more	-	09 Jul 2024
				Fulvestrant+Mirdametinib (Arm 1, Part 2 - Mirdametinib in Combination With Fulvestrant)	ttdopoeezm(ouefzxiusp) = zpdnkilqnt isctaphhwo (miziyrplxk, mvodtsleqs - luyymmnmnh) View more
NCT03962543 (ReNeu, ASCO2024) Manual	Phase 2	NF1 mutant Plexiform Neurofibroma	114	Mirdametinib 2 mg/m2 BID	mtsfwhugtn(ggvfwezwvr) = dmfhuswufl uscsillqzb (qmtiwfprry, 29 - 55) View more	Positive	24 May 2024
				Mirdametinib (pediatric)	mtsfwhugtn(ggvfwezwvr) = wohdzyzqqj uscsillqzb (qmtiwfprry, 38 - 65) View more
NCT03962543 (ReNeu, GlobeNewswire) Manual	Phase 2	Plexiform Neurofibroma NF1	114	Mirdametinib (pediatric patients)	fkdxtistzy(jattcejwxr) = loeuwqjepc ftinyrnrbd (tiilmuajct ) View more	Positive	16 Nov 2023
				Mirdametinib (adult patients)	fkdxtistzy(jattcejwxr) = lsnxvcbjfo ftinyrnrbd (tiilmuajct ) View more